Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 6/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503942 | 0.76 | KEAP1 (0.36) | KEAP1NFE2L2CTSLCTSBCTSS | |
| SCHEMBL5504083 | 0.71 | KEAP1 (0.36) | KEAP1NFE2L2CNR1CNR2STAT3 | |
| SCHEMBL6009956 | 0.69 | HPGD (0.36) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL6009060 | 0.69 | KEAP1 (0.37) | KEAP1NFE2L2STAT3ALDH1A1LMNA | |
| SCHEMBL17995187 | 0.63 | KEAP1 (0.39) | KEAP1NFE2L2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6008635 | 0.63 | GRIA4 (0.40) | KEAP1NFE2L2STAT3ALDH1A1LMNA | |
| SCHEMBL13518307 | 0.63 | KMT2A (0.51) | KEAP1NFE2L2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5504957 | 0.62 | — | — | |
| SCHEMBL12320434 | 0.60 | ACHE (0.39) | CNR1CNR2STAT3ALDH1A1LMNA | |
| SCHEMBL9728886 | 0.59 | CHRNA7 (0.35) | KEAP1NFE2L2CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | KEAP1 1179/4885NFE2L2 2049/4885CTSL 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.